GlassScriptPhysician profile
Daniel Thomas Nevin
NPI 1013126416
$2,059.37
in general payments reported to CMS, 2019-2025
17 companies · $412 in 2025
The $412 reported for 2025 was more than what 85% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $438 · 2023: $360 · 2024: $748 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Education: $34.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.43 |
| Education | $34.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $627.85 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $437.09 | 2021-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $251.65 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $157.01 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $121.24 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $70.72 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $70.32 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $67.95 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $46.92 | 2025 | |
| Intercept Pharmaceuticals, INC. | $46.36 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $37.29 | 2022-2023 | |
| Braintree Laboratories, INC. | $29.24 | 2022 | |
| Genzyme Corporation | $28.68 | 2023 | |
| Madrigal Pharmaceuticals | $22.50 | 2024 | Resmetirom |
| Ferring Pharmaceuticals INC. | $16.12 | 2023 | Rebyota |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $15.62 | 2024 | Iqirvo |
| Redhill Biopharma INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nevin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.